PerkinElmer Receives CE Mark for Multi-analyte Respiratory Panel Including COVID-19
PerkinElmer, Inc. (NYSE: PKI) announced today that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has received clearance to be marketed as an in vitro diagnostic (IVD) device in more than 30 countries by meeting the requirements of the European In Vitro Diagnostic Directive (IVDD). This test is currently under review by the U.S. FDA for Emergency Use Authorization (EUA). The multi-analyte panel enables labs to detect and differentiate between SARS-CoV-2, influenza A viruses, influenza B viruses and respiratory syncytial virus (RSV) in a single test, which will be critical to manage the surge in test demand during the flu season as the targeted pathogens have some similar signs and symptoms.
Rather than running multiple tests on samples, the PKamp Respiratory SARS-CoV-2 RT-PCR Panel is designed to conserve resources by testing a single nasopharyngeal, oropharyngeal or nasal swab sample collected from individuals suspected of respiratory viral infection consistent with COVID-19, the flu and RSV. Building off the most sensitive SARS-CoV-2 test kit in the market according to the FDA’s reference panel comparative data, the multi-analyte panel is designed to be used with PerkinElmer’s automated viral nucleic extractor to detect smaller amounts of viral material in samples.
“In the next few months, it will be vital for health professionals to detect and differentiate between COVID-19, the common flu and RSV infection,” said Masoud Toloue, Ph.D., Vice President and General Manager, Diagnostics, PerkinElmer. “By offering an automated multi-analyte testing solution, we are equipping diagnostics labs with the right toolset to tackle the additional pressure the season may have on this pandemic.”
PerkinElmer continues to work with specialty and reference diagnostic labs, clinics, hospitals, pharmaceutical and biopharmaceutical labs, academia, and governmental and research institutes to battle the pandemic. PerkinElmer’s comprehensive SARS-CoV-2 offerings span high throughput RNA extraction, RT-PCR, automation, ELISA, chemiluminescence, time-resolved fluorescence and lateral flow based serology testing.
About PerkinElmer
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005308/en/
Contact information
Media Relations:
Chet Murray
(781) 663-5719
chet.murray@perkinlelmer.com
Investor Relations:
Bryan Kipp
(781) 663-5583
bryan.kipp@perkinelmer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H2SITE Strengthens Its Leadership With a New Control Room, Developed in Collaboration With Siemens, to Remotely Monitor Membrane Reactor and Separator Technologies for Hydrogen Production Across Europe27.10.2025 13:01:00 EET | Press release
H2SITE, the deep-tech start-up revolutionizing high-purity hydrogen production through cutting-edge palladium membrane technology, is scaling up its industrial presence with projects deployed across several European countries. To ensure performance and continuous optimization of its membrane reactors and separators, H2SITE has launched a control and data collection room built in collaboration with Siemens, based on the beta version of Siemens WinCC Unified Collaboration and Datahub software. The control room is already integrated and will be further developed across various ongoing and future projects, covering a wide range of market segments that reflect the versatility of H2SITE’s membrane-based technology. In the field of ammonia (NH₃) cracking, projects such as EIC, APOLO, and KATA are integrating this tool to monitor hydrogen production efficiency and system reliability in real time. Within the Waste-to-Hydrogen (WtH₂) segment, the HYIELD project is applying the control room to op
Comply Acquires Trailight to Accelerate Global Expansion and Create the Industry’s First Fully Integrated Firm and Employee Compliance Platform27.10.2025 11:07:00 EET | Press release
Comply, the leading provider of regulatory and compliance technology solutions for financial firms, today announced it has acquired Trailight, the U.K.’s leading provider of purpose-built solutions for managing conduct risk, competence frameworks, and global accountability regimes. With the addition of Trailight, Comply becomes the first and only unified compliance platform to bring together firm compliance, employee compliance, individual accountability regime and archiving solutions across jurisdictions. The acquisition strengthens Comply’s growing presence in Europe, where demand for modern, integrated compliance solutions continues to accelerate amid expanding regulatory frameworks and accountability mandates. “Over the past year, we’ve seen remarkable growth across Europe as firms seek to consolidate their compliance technology and gain greater transparency into both firm and employee obligations,” said Michael Stanton, CEO of Comply. “Trailight is the perfect complement to that s
Colorectal, Liver, and Lung Cancer Patients at Vinmec Experience Extended Survival with AIET Cell-Based Immunotherapy – Technology Transferred from Japan27.10.2025 08:39:00 EET | Press release
Significantly extended survival and improved quality of life (QoL) for cancer patients achieved through autologous cell-based AIET immunotherapy, utilizing patients' own natural killer (NK) cells and T cells, has positioned Vinmec Hospital, Vietnam, as an emerging medical tourism destination for cancer treatment across Asian countries. This accomplishment was presented by Professor Nguyen Thanh Liem at the NCRM NICHE 2025. He acknowledged the technology transfer support from GN Corporation, Japan, enabling the implementation of standardized AIET protocols in accordance with Japanese regulations, bringing treatment access to patients at Vinmec since 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251026088789/en/ Professor Nguyen Thanh Liem, Director, Institute of Stem Cell and Genetic Technology Research at Vinmec International Hospital, Hanoi, Vietnam and his team have successfully implemented the technology transfer o
METI will hold GGX Finance Summit27.10.2025 08:30:00 EET | Press release
On November 5 (Wed), the Ministry of Economy, Trade and Industry (METI) will hold the GGX Finance Summit at The Capitol Hotel Tokyu and on-line. In order to further develop discussions on transition finance, industry decarbonization, and other topics related to how business and finance contribute to decarbonization, we will promote mutual cooperation between the government, business, and financial sectors, and hold discussions to lead the international rule-making process to achieve both emission reductions and economic growth. Outline of GGX Finance Summit Date: November 5th, 2025 10:00-16:45 (JST, GMT+9:00) Venue: The Capitol Hotel Tokyu (Tokyo) (2-10-3, Nagata-cho, Chiyoda-ku, Tokyo 100-0014, Japan) Organizer: Ministry of Economy, Trade and Industry (METI), GX Acceleration Agency Co-organizer: World Business Council for Sustainable Development (WBCSD), TCFD Consortium Format: Hybrid (On-site and on-line) Language: Japanese/English (with English/Japanese simultaneous interpretation)
NITMX, Ant International and Krungthai Bank Expand Payment Connectivity Between Thailand and China via PromptPay27.10.2025 05:37:00 EET | Press release
Under the guidance of the Bank of Thailand, Ant International, a leading global digital payment, digitisation and financial technology provider and National ITMX will partner to enhance and promote payments connectivity via PromptPay, between Thai merchants and Chinese consumers, which will be launched soon. Krungthai Bank will be the settlement bank for this cross-border QR partnership. In the initial phase, Chinese travellers to Thailand can use Alipay, an Alipay+ e-wallet partner, to make QR payment at millions of local merchants by scanning the PromptPay QR. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251026429360/en/ The partnership will facilitate Chinese tourists’ spending in Thailand while also expanding income opportunities for small and medium-sized enterprises (SMEs) across the country. Introduced by the Bank of Thailand in 2016, and operated by NITMX, PromptPay is the national payment infrastructure of Thailan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom